Reading PHR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PHR free→Reading PHR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PHR free→
NYSEHealth CareHealth Information ServicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, but risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 26% above where it trades (it looks cheap on this basis); the read is fair, quality intact. Key factors to watch include guidance changes and sector trends, as these could significantly impact estimates and stock performance. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $9.14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $9.14 PHR trades at 13× p/e, below its 15× p/e peer median. Our $12 fair value sits above the price; medium confidence. Analysts: $9.00–$16. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 23% below a flat-multiple fair value, below our forecast of about 17%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 9.57x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.33 → $0.32 (-2.1% / 30d). 5 raised, 3 cut, 10 covering analysts.
0 upgrades, 1 downgrade / 30d, 4 maintained. 60% of analysts rate Buy.
5 PT revisions / 30d. Avg target 34.3% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$158.
How much price usually moves either way.
On a bad day, this stock has moved -$519.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,524.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth picks up, it could indicate a positive shift for Phreesia's market.
Confirms:3-year revenue growth in the health care sector rises above 12 percent.
Disproves:3-year revenue growth in the health care sector stays below 10 percent.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PHR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition On May 27, 2026, Phreesia, Inc. (the “Company”) announced its financial results for the fiscal first quarter ended April 30, 2026 by issuing a stakeholder letter (the "Letter") and a press release. Copies of the press release and the Letter are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein. The information furnished under this
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$9.00 – $16.00 (median $12.00) · 6 analysts · as of 2026-05-28
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2026-Q1, 2026-Q2, 2026-Q3, 2027-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PHR Phreesia, Inc. | Typical Show detailsSector percentile: 56 of 100 | fair | high |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 79 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Phreesia aims to achieve revenue growth within the range of $510 million to $520 million for fiscal year 2027.
Stated in 3 of last 3 quarters. Revenue grew from $109.68M in 2025-Q4 to $130.94M in 2027-Q1, showing progress towards the $510M-$520M FY 2027 target. The trajectory indicates delivering on growth expectations.
“We expect revenue to be in the range of $510 million to $520 million.”
“We now expect revenue to be in a range of $510 million to $520 million.”
“We expect revenue to be in the range of $510 million to $520 million.”
Phreesia maintains its adjusted EBITDA outlook of $125 million to $135 million for fiscal year 2027.
Stated in 3 of last 3 quarters. While specific EBITDA figures are not provided in the financials, the consistent guidance suggests a focus on achieving the $125M-$135M target. The trajectory remains to be fully substantiated by financial results.
“We expect Adjusted EBITDA to be in the range of $125 million to $135 million.”
Phreesia is implementing a restructuring plan to reduce operating expenses and align cost structure with business priorities.
Newly stated in 2026-Q1. The restructuring plan aims to reduce operating expenses, but specific cost savings are not detailed in the financials. The impact on operating expenses will need further observation in subsequent quarters.
“Phreesia implemented a restructuring plan to reduce operating expenses.”
Entry into a Material Definitive Agreement On April 30, 2026 (the “Closing Date”), AccessOne Funding, LLC (“AccessOne Funding”), an indirect wholly-owned subsidiary of Phreesia, Inc., a Delaware corporation (“Phreesia” or the “Company”), as seller, AccessOne MedCard, Inc. (“AccessOne MedCard”), an indirect wholly-owned subsidiary of Phreesia, as servicer, PNC Bank, National Association (“PNC”), as purchaser and administrative agent, and PNC Capital Markets LLC (“PNC Capital Markets”), as stru…
Other Events. On May 7, 2026, Phreesia, Inc. (the “Company”) implemented a restructuring plan intended to reduce operating expenses and better align the Company’s cost structure with its current business priorities. The plan includes the recent elimination of approximately 220 positions, approximately half of which are contractor roles. The Company does not expect the costs associated with the plan to be material and expects such costs to be incurred primarily during fiscal year 2027. The Com…
Forward Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include, but are not limited to, statements about the Receivables Purchase Agreement, the Amendment and the Amended and Restated Performance Guaranty and are generally identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strateg…
and in the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. Forward Looking Statements This Current Report on Form 8-K contains certain forward-lookin…
“We are maintaining our adjusted EBITDA outlook of $125 million to $135 million.”
“We are maintaining our Adjusted EBITDA outlook for fiscal 2027.”